The third-generation EGFR kinase inhibitor osimertinib, originally designed to overcome drug resistance caused by the secondary EGFR T790M mutation, has become favored as a first-line therapy in the context of classical EGFR mutant NSCLC based on impressive median PFS of >18 months [32]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.